Blood pressure has only minor influence on aldosterone-induced oxidative stress and DNA damage in vivo

Free Radical Biology and Medicine

Volumn 54, Issue , 2013, Pages 17-25

  Queisser, Nina ^a   Amann, Kerstin ^b   Hey, Valentin ^a   Habib, Samy L ^c   Schupp, Nicole ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c University of Texas Health Science Center at San Antonio   (United States)

Author keywords

8 OxodG; Aldosterone; Free radicals; Hypertension; Kidney disease; Mineralocorticoid receptor; NF B

Indexed keywords

ALDOSTERONE; HYDRALAZINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE; TEMPOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; HISTOPATHOLOGY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KIDNEY CELL; KIDNEY INJURY; MALE; MICROALBUMINURIA; MUTAGENESIS; NITRATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; URINALYSIS;

ALDOSTERONE; ANIMALS; APOPTOSIS; BLOOD PRESSURE; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CYCLIC N-OXIDES; DNA DAMAGE; HYDRALAZINE; HYPERTENSION; KIDNEY; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NF-KAPPA B; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTORS, MINERALOCORTICOID; SPIN LABELS; SPIRONOLACTONE;

RATTUS;

EID: 84870208124     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2012.10.549     Document Type: Article

References (55)

1. J.M. Connell, and E. Davies The new biology of aldosterone J. Endocrinol. 186 2005 1 20
2. G.P. Rossi, G. Bernini, and C. Caliumi A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients J. Am. Coll. Cardiol 48 2006 2293 2300
3. R.D. Gordon, M.D. Ziesak, T.J. Tunny, M. Stowasser, and S.A. Klemm Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers Clin. Exp. Pharmacol. Physiol 20 1993 296 298
4. D.A. Calhoun, D. Jones, and S. Textor Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Circulation 117 2008 e510 526
5. M.J. Young, and A.J. Rickard Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis Mol. Cell. Endocrinol 350 2012 248 255
6. V.G. Fourkiotis, G. Hanslik, F. Hanusch, J. Lepenies, and M. Quinkler Aldosterone and the kidney Horm. Metab. Res. 44 2012 194 201
7. S. Friis, H.T. Sorensen, and L. Mellemkjaer Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark Cancer 92 2001 2462 2470
8. L.E. Moore, R.T. Wilson, and S.L. Campleman Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: a review Cancer Invest. 23 2005 240 255
9. P. Meyer Increased intracellular calcium: from hypertension to cancer J. Hypertens. Suppl. 5 1987 S3 4
10. P. Hamet Cancer and hypertension: an unresolved issue Hypertension 28 1996 321 324
11. J.W. Funder Reconsidering the roles of the mineralocorticoid receptor Hypertension 53 2009 286 290
12. N. Queisser, P.I. Oteiza, H. Stopper, R.G. Oli, and N. Schupp Aldosterone induces oxidative stress, oxidative DNA damage and NF-kappaB-activation in kidney tubule cells Mol. Carcinog 50 2011 123 135
13. G. Corrao, L. Scotti, V. Bagnardi, and R. Sega Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis. Curr Drug Saf. 2 2007 125 133
14. U. Schmid, H. Stopper, F. Schweda, N. Queisser, and N. Schupp Angiotensin II induces DNA damage in the kidney Cancer Res 68 2008 9239 9246
15. N. Schupp, P. Kolkhof, and N. Queisser Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats FASEB J. 25 2011 968 978
16. A. Virdis, M.F. Neves, F. Amiri, E. Viel, R.M. Touyz, and E.L. Schiffrin Spironolactone improves angiotensin-induced vascular changes and oxidative stress Hypertension 40 2002 504 510
17. C.S. Ceron, M.M. Castro, and E. Rizzi Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension Br. J. Pharmacol 160 2010 77 87
18. J.H. Westhoff, K.F. Hilgers, and M.P. Steinbach Hypertension induces somatic cellular senescence in rats and humans by induction of cell cycle inhibitor p16INK4a Hypertension 52 2008 123 129
19. M.R. Lamprecht, D.M. Sabatini, and A.E. Carpenter CellProfiler: free, versatile software for automated biological image analysis Biotechniques 42 2007 71 75
20. S.L. Habib, B.K. Bhandari, N. Sadek, S.L. Abboud-Werner, and H.E. Abboud Novel mechanism of regulation of the DNA repair enzyme OGG1 in tuberin-deficient cells Carcinogenesis 31 2010 2022 2030
21. F.S. Michel, G.R. Norton, and O.H. Majane Contribution of circulating angiotensinogen concentrations to variations in aldosterone and blood pressure in a group of African ancestry depends on salt intake Hypertension 59 2012 62 69
22. S. Morizane, F. Mitani, and K. Ozawa Biphasic time course of the changes in aldosterone biosynthesis under high-salt conditions in dahl salt-sensitive rats Arterioscler. Thromb. Vasc. Biol 32 2012 1194 1203
23. N. Queisser, N. Schupp, H. Stopper, R. Schinzel, and P.I. Oteiza Aldosterone increases kidney tubule cell oxidants through calcium-mediated activation of NADPH oxidase and nitric oxide synthase Free Radic. Biol. Med 51 2011 1996 2006
24. M.A. Bayorh, A. Rollins-Hairston, J. Adiyiah, D. Lyn, and D. Eatman Eplerenone suppresses aldosterone/salt-induced expression of NOX-4 J. Renin Angiotensin Aldosterone Syst 12 2011 195 201
25. H. Cai, and D.G. Harrison Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress Circ. Res 87 2000 840 844
26. N.D. Vaziri Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension Curr. Opin. Nephrol. Hypertens 13 2004 93 99
27. -• or as SOD mimics? J. Biol. Chem 271 1996 26026 26031
28. C.S. Wilcox Effects of tempol and redox-cycling nitroxides in models of oxidative stress Pharmacol. Ther 126 2010 119 145
29. P.K. Chatterjee, S. Cuzzocrea, and P.A. Brown Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat Kidney Int 58 2000 658 673
30. P.J. McKinnon, and K.W. Caldecott DNA strand break repair and human genetic disease Annu. Rev. Genomics Hum. Genet 8 2007 37 55
31. P.A. Jeggo, and M. Lobrich DNA double-strand breaks: their cellular and clinical impact? Oncogene 26 2007 7717 7719
32. Y. Nakabeppu, K. Sakumi, K. Sakamoto, D. Tsuchimoto, T. Tsuzuki, and Y. Nakatsu Mutagenesis and carcinogenesis caused by the oxidation of nucleic acids Biol. Chem 387 2006 373 379
33. C. Trapp, M. Schwarz, and B. Epe The peroxisome proliferator WY-14,643 promotes hepatocarcinogenesis caused by endogenously generated oxidative DNA base modifications in repair-deficient Csbm/m/Ogg1-/- mice Cancer Res 67 2007 5156 5161
34. I.H. Ismail, and M.J. Hendzel The gamma-H2A.X: is it just a surrogate marker of double-strand breaks or much more? Environ. Mol. Mutagen 49 2008 73 82
35. J.T. Mathew, H. Patni, and A.N. Chaudhary Aldosterone induces mesangial cell apoptosis both in vivo and in vitro Am. J. Physiol. Renal Physiol 295 2008 F73 81
36. W. Liang, C. Chen, and J. Shi Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats Nephrol. Dial. Transplant 26 2011 789 799
37. J.G. Burniston, A. Saini, L.B. Tan, and D.F. Goldspink Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo J. Mol. Cell. Cardiol 39 2005 395 399
38. A. Nishiyama, L. Yao, and Y. Nagai Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats Hypertension 43 2004 841 848
39. A. Nishiyama, L. Yao, and Y. Fan Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability Hypertension 45 2005 710 716
40. Y. Habraken, and J. Piette NF-kappaB activation by double-strand breaks Biochem. Pharmacol. 72 2006 1132 1141
41. G. Gloire, S. Legrand-Poels, and J. Piette NF-kappaB activation by reactive oxygen species: fifteen years later Biochem. Pharmacol 72 2006 1493 1505
42. G. Sethi, B. Sung, and B.B. Aggarwal Nuclear factor-kappaB activation: from bench to bedside Exp. Biol. Med. (Maywood, NJ) 233 2008 21 31
43. S.U. Sonder, A. Woetmann, N. Odum, and K. Bendtzen Spironolactone induces apoptosis and inhibits NF-kappaB independent of the mineralocorticoid receptor Apoptosis 11 2006 2159 2165
44. S. Fukuda, C. Horimai, and K. Harada Aldosterone-induced kidney injury is mediated by NFkappaB activation. Clin Exp. Nephrol. 15 2011 41 49
45. R.A. Beswick, H. Zhang, D. Marable, J.D. Catravas, W.D. Hill, and R.C. Webb Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response Hypertension 37 2 Part 2 2001 781 786
46. P. Hogendorf, A. Durczynski, A. Kumor, and J. Strzelczyk Prostaglandin E2 (PGE2) in portal blood in patients with pancreatic tumor - a single institution series J. Invest. Surg 25 2012 8 13
47. R.T. Hui, J.H. Grose, M. Lebel, and P. Falardeau Prostanoids and aldosterone-induced mild experimental hypertension in rats Hypertension 15 1990 198 203
48. E.A. Jaimes, M.S. Zhou, D.D. Pearse, L. Puzis, and L. Raij Upregulation of cortical COX-2 in salt-sensitive hypertension: role of angiotensin II and reactive oxygen species Am. J. Physiol 294 2008 F385 392
49. M. Honda, and M. Hatano Influence of spironolactone on urinary prostaglandin E2 and kinin excretion in rats Prostaglandins Leukotrienes Essent. Fatty Acids 31 1988 17 21
50. T.B. Fraser, S.W. Turner, G.J. Mangos, J. Ludbrook, and J.A. Whitworth Comparison of telemetric and tail-cuff blood pressure monitoring in adrenocorticotrophic hormone-treated rats Clin. Exp. Pharmacol. Physiol 28 2001 831 835
51. J. Ibrahim, B.C. Berk, and A.D. Hughes Comparison of simultaneous measurements of blood pressure by tail-cuff and carotid arterial methods in conscious spontaneously hypertensive and Wistar-Kyoto rats Clin. Exp. Hypertens 28 2006 57 72
52. J.A. Shapiro, M.A. Williams, N.S. Weiss, A. Stergachis, A.Z. LaCroix, and W.E. Barlow Hypertension, antihypertensive medication use, and risk of renal cell carcinoma Am. J. Epidemiol. 149 1999 521 530
53. A.S. Bomback, and P.J. Klemmer Mineralocorticoid receptor blockade in chronic kidney disease Blood Purif 33 2012 119 124
54. A. Chrysostomou, E. Pedagogos, L. MacGregor, and G.J. Becker Double-blind placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker Clin. J. Am. Soc. Nephrol 1 2006 256 262
55. L. Tylicki, P. Rutkowski, and M. Renke Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial Am. J. Kidney Dis 52 2008 486 493